Bausch Health Companies Inc. (BHC.TO) on Friday said its Phase 3 RED-C clinical program evaluating amorphous rifaximin solid soluble dispersion (SSD) in adults with liver cirrhosis for the primary prevention of hepatic encephalopathy (HE) did not meet its primary endpoint.
The RED-C program includes two Phase 3 trials assessing rifaximin SSD for delaying the first episode of HE in adults with liver cirrhosis who have no prior HE episodes.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.